General considerations in relapsed myeloma
| Variable . | Considerations . |
|---|---|
| Components of the initial therapy | Novel agents? |
| ASCT? | |
| Degree and duration of response to primary therapy | PR, VGPR, CR? |
| ≥6 mo, ≥1 y? | |
| Previous toxicities | Myelosuppression |
| Peripheral neuropathy | |
| Type of relapse | Aggressive |
| Indolent | |
| Age and performance status | Elderly |
| Frail |
| Variable . | Considerations . |
|---|---|
| Components of the initial therapy | Novel agents? |
| ASCT? | |
| Degree and duration of response to primary therapy | PR, VGPR, CR? |
| ≥6 mo, ≥1 y? | |
| Previous toxicities | Myelosuppression |
| Peripheral neuropathy | |
| Type of relapse | Aggressive |
| Indolent | |
| Age and performance status | Elderly |
| Frail |